Compatibility «Lisinopril» and «Telmisartan»
Between «Lisinopril» and «Telmisartan» found 8 dangerous and 10 negative interactions, joint admission is not recommended without consulting a doctor.
Interaction tableCompare |
Telmisartan |
✘Lisinopril Analogs | |
✘Telmisartan Analogs |
-
Interactions Lisinopril with Telmisartan
-
Dangerous interactions
Double blockade of RAAS ARA II, ACE inhibitors or direct renin inhibitors (such as aliskiren) It is associated with an increased risk of hypotension, syncope, hyperkalemia and changes in renal function (including acute renal failure) compared to monotherapy. In patients with atherosclerotic disease, heart failure or diabetes mellitus with target organ damage, simultaneous therapy with ACE inhibitor and ARA II is associated with a higher incidence of arterial hypotension, syncope, hyperkalemia and deterioration of renal function (including acute renal failure) compared with the use of only one drug that affects the RAAS. Concomitant use of ACE inhibitors with ARA II is contraindicated in patients with diabetic nephropathy and is not recommended in other patients. With simultaneous use of lisinopril with potassium-sparing diuretics (spironolactone, triamterene, amiloride, eplerenone), potassium preparations or potassium-containing substitutes for table salt and other drugs capable of increasing the potassium content in blood serum (including ARA II, heparin, tacrolimus, cyclosporine; preparations containing co-trimoxazole [trimethoprim + sulfamethoxazole]), the risk of hyperkalemia increases (especially in patients with impaired renal function). In some patients with impaired renal function (for example, in elderly patients or patients with dehydration) receiving NSAID therapy (in pm with selective COX-2 inhibitors), the simultaneous use of ACE inhibitors or ARA II may cause further deterioration of renal function, including the development of acute renal failure, and hyperkalemia. ACE inhibitors (C09A) + angiotensin ii receptor antagonists => Are associated with an increased risk of arterial hypotension, syncope, hyperkalemia and impaired renal function (in pm acute renal failure) compared with monotherapy. With the simultaneous use of lithium preparations and ACE inhibitors or ARA II, including telmisartan, there was a reversible increase in the concentration of lithium in blood plasma, accompanied by toxic effects. Clinical studies have shown that double blockade of the renin-angiotensin-aldosterone system (RAAS) due to the combined use of ACE inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse reactions such as hypotension, hyperkalemia and decreased renal function (including acute renal failure) compared with the use of a single agent acting on RAAS (see sections 'Contraindications', 'Special instructions' and 'Pharmacodynamics'). -
Negative interactions
The possibility of hypotensive effects when taking lisinopril can be minimized by reducing or stopping the diuretic or increasing salt intake before starting treatment with lisinopril. Double blockade (for example, when combining an ACE inhibitor with ARA II) should be limited to individual cases with careful monitoring of renal function, potassium content and regular blood pressure monitoring. Other antihypertensive drugs. When used simultaneously with vasodilators, beta-blockers, BMCC, diuretics and other antihypertensive drugs, the severity of the antihypertensive effect of lisinopril increases. Blood pressure should be carefully monitored and, if necessary, the dose of antihypertensive drugs should be adjusted. The risk may increase when combined with other medications that can also provoke hyperkalemia (salt substitutes containing potassium, potassium‑sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, nonsteroidal anti‑inflammatory drugs (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressants (cyclosporine or tacrolimus) and co-trimoxazole (trimethoprim + sulfamethoxazole). Concomitant use with ACE inhibitors or NSAIDs, including selective COX‑2 inhibitors, is accompanied by a lower risk of hyperkalemia, provided careful observance of precautions. Other antihypertensive agents. The effect of telmisartan on lowering blood pressure can be enhanced by simultaneous administration of other antihypertensive medications. Based on their pharmacological properties, it can be expected that the following drugs can enhance the antihypertensive effect of all antihypertensive agents, including telmisartan: baclofen, amifostin.
-
Dangerous interactions
Decoding the colors of interactions and contraindications
Dangerous | — | a pronounced negative interaction or contraindication. |
Negative | — | negative interaction or side effect that may reduce effectiveness. |
Positive | — | the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication of the drug. |
No | — | the drugs do NOT interact, which is separately indicated in the instructions. |
Unclear | — | the system failed to pre-assess the danger. |
Video instruction
Additional information
- Kiberis checks interactions and evaluates drug compatibility for free online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
- Why do I need to
- Avoid dangerous prescriptions for your patients.
- Check the contraindications.
- Evaluate the safety of therapy in the treatment of children.
- See the compatibility of drugs with alcohol (enter it as a drug).
- Point the doctor to the found interaction - you may need to adjust the therapy.
- The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
- The article is written: artificial intelligence Kiberis
- Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
- Total analyzed: 169,976,234 possible combinations of drugs and their components were found 412,512 interacting combinations.
- Medicine section: Standard evidence-based medicine
- The date of the last update of the interaction database: 2024-05-23
Category - medicine